ArticleOpen forum infectious diseases2020
Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Distrust in the Health Care System and Adherence to Direct-Acting Antiviral Therapy among People with HepatitisViruses · 2024Trial
- 2025 KASL clinical practice guidelines for management of hepatitis C.Clinical and molecular hepatology · 2026Article
- Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Reply to: "Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma".JHEP reports : innovation in hepatology · 2024Article
- Like a Rolling Stone? A Review on Spontaneous Clearance of Hepatitis C Virus Infection.Viruses · 2024Review
- To decline or not to decline: Consequences of decision-making regarding lung offers from donors with hepatitis C.The Journal of thoracic and cardiovascular surgery · 2024Article
- DNA-directed formation of plasmonic core-satellite nanostructures for quantification of hepatitis C viral RNA.Chemical science · 2024Article
- Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.JHEP reports : innovation in hepatology · 2024Article
- Risk factors and outcome of hepatitis C infection among patients in a secondary care hospital: A 5-year retrospective study.Journal of education and health promotion · 2024Article
- Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures.BMJ case reports · 2023Article
- Statin Utilization Among Individuals Infected With Hepatitis C Virus: A Retrospective Cohort Study.Cureus · 2023Article
- The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.PloS one · 2023Article
- Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective.Journal of managed care & specialty pharmacy · 2022Article
- Breakthroughs in hepatitis C research: from discovery to cure.Nature reviews. Gastroenterology & hepatology · 2022Review
- Hepatitis C cure as a 'gathering': Attending to the social and material relations of hepatitis C treatment.Sociology of health & illness · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDirect-acting antiviral (DAA) therapies for hepatitis C virus (HCV) result in initial cure rates of 95% to 99% and re-treatment cure rates of 95%. Nevertheless, given the sheer magnitude of infected persons, some will ultimately fail multiple DAA therapies, and re-treatment of these persons has not been adequately studied.
methodsWe evaluated treated an HIV-infected man with cirrhosis from genotype 1b HCV who had failed 3 DAA regimens.
resultsWe treated and cured our "particularly difficult-to-cure" patient with sofosbuvir plus glecaprevir/pibrentasvir plus ribavirin for 24 weeks. We discuss the literature on potential biological factors behind his treatment failures such as lack of HCV seroconversion during his infection course, and multiple failures of hepatitis B seroconversion after vaccination, and the rationale for choosing his curative salvage regimen. DISCUSSION: There are no clinical trials-proven re-treatment regimens for "particularly difficult-to-cure" patients. Multiple patient- and virus-related factors that do not affect cure rates in treatment-naive patients may need to be considered in choosing a re-treatment regimen for these patients. These regimens may need to include combinations drugs that are not available in single-tablet form, addition of ribavirin, and longer durations of treatment than standard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.